Here are the latest CSL/ASX updates I can share from recent public announcements and coverage up to early 2026:
-
CSL (ASX: CSL) has been active with quarterly updates and strategic news, including profit guidance and notable collaborations in 2025, as reported in CSL’s global newsroom and ASX announcements [CSL: financial results and strategic updates, 2025-2026].
-
Key 2025 milestones included CSL’s announced profit growth for the full year 2025 (net profit after tax around US$3.0 billion reported, with underlying results benefiting from ongoing operations across CSL Behring, CSL Seqirus, and CSL Vifor) and updates on collaborations such as the VarmX partnership, which CSL disclosed in 2025 [CSL Newsroom 2025; ASX announcements 2025].
-
CSL Seqirus (the influenza vaccines arm) highlighted recent research presentations and portfolio updates in late 2025, reflecting ongoing investment in seasonal influenza prevention and related vaccine programs [CSL Seqirus updates, 2025].
-
There have been routine buy-back notifications and board-level changes in 2025–early 2026, as CSL continues to manage capital allocation and governance, per CSL and major investor sites [CSL announcements 2025; ASX communications].
-
For investors, CSL’s official channels (the global newsroom and ASX listings) remain the primary sources for fresh press releases, quarterly results, and governance updates; they often summarize strategic partnerships, product developments, and financial performance [CSL newsroom; ASX CSL page].
If you’d like, I can pull the most recent specific headlines (with dates and short summaries) from CSL’s newsroom and ASX announcements and present them in a concise timeline, or I can fetch current share-price context and recent analyst commentary from 2026. Would you like a focused update on:
- 2025–2026 financial results and outlook,
- CSL Seqirus influenza vaccine program updates, or
- Recent strategic collaborations and their implications? I can also provide a compact table comparing the key developments across CSL Behring, CSL Seqirus, and CSL Vifor.
Sources
INTENDED FOR MEDIA AND BUSINESS INVESTORS ONLY Summit, New Jersey, USA 21 October, 2025 – CSL Seqirus, a global leader in seasonal influenza prevention (ASX: CSL), has shared new actionable... Oct 17, 2025CSL Seqirus Presents Latest Research Across Leading Seasonal Influenza Vaccine Portfolio at ESWI 2025 … Melbourne, Australia – 16 September 2025 CSL today announced it has entered into a strategic collaboration with privately held Dutch biotech company VarmX BV to support the company’s... Aug...
newsroom.csl.comMelbourne, Australia – 16 September 2025 CSL today announced it has entered into a strategic collaboration with privately held Dutch biotech company VarmX BV to support the company’s... Aug 18, 2025CSL announces rise in full year net profit Global biotherapeutics leader CSL today announced a reported net profit after tax of US$3.0 billion for the 12 months ended 30 June 2025, up 17% on a constant currency basis. Underlying profit... … Feb 11, 2024CSL Announces Top-line Results from the Phase 3...
newsroom.csl.comCSL Limited (ASX:CSL) (OTCMKTS:CSLLY) is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL вҖ“ including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor вҖ“ provides lifesaving...
abnnewswire.netCSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Together they help ensure people everywhere get the treatments they need.
investors.csl.comAll the latest CSL (ASX:CSL) share price movements, news, expert commentary and investing advice from The Motley Fool Australia.
www.fool.com.auCSL Limited (ASX:CSL) company ASX announcements at IntelligentInvestor.com.au
www.intelligentinvestor.com.auTiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.
www.itiger.comCSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Together they help ensure people everywhere get the treatments they need.
investors.csl.com